Company / Operating Cash Flow per Share
Immunovant, Inc. Operating Cash Flow per Share History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$2.48
FY2024
5-year range
-$2.48 / -$0.95
FY2020-FY2024
Trend
-59.9%
vs FY2023
Sector context
#154 of 210
Health Care
What the data says
At $-2.48, Immunovant, Inc.'s operating cash flow per share ranks #154 of 210 in the Health Care sector. Operating Cash Flow per Share has declined for 4 consecutive years, from $-0.95 in FY2020 to $-2.48 in FY2024.
Based on SEC 10-K filings.
-2.48 in FY2024.
Declined from $-1.53 to $-2.48 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#154 of 210 in Health CareTop 73% of 210This company -$2.48 Sector average $5.30
▼
-146.8% below sector average
Key checks
Key Insights
- Immunovant, Inc.'s operating cash flow per share has declined for 4 consecutive years.
- In FY2024, operating cash flow per share decreased 59.9% year-over-year.
- Ranks #154 out of 210 companies in the Health Care sector.
- Peak operating cash flow per share was recorded in FY2020.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$2.48 | -59.9% |
| FY2023 | -$1.55 | -1.4% |
| FY2022 | -$1.53 | -58.0% |
| FY2021 | -$0.97 | -1.9% |
| FY2020 | -$0.95 | +23.1% |
| FY2019 | -$1.24 | +4.1% |
| FY2018 | -$1.29 | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026